Patterns of response to anti-CGRP monoclonal antibodies during first 6-months of treatment in resistant migraine patients: impact on outcome.

Marta Torres-FerrúsVictor J GallardoAlicia AlpuenteEdoardo CaronnaEulalia Giné-CiprésPatricia Pozo-Rosich

Published in: European journal of neurology (2023)

Initial response to anti-CGRP MAbs is not consistent in all patients. Persistence of anxiety and depression might be associated with lower response rates at month 6.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
peritoneal dialysis